HCID 58075556, compound → HCID 58075303, compound
Reaction equation
[Cl:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:12]=[CH:11][C:10]([NH:13][C:14]3[N:15]=[C:16]([NH:34][CH3:35])[C:17]4[CH2:22][CH2:21][CH:20]([C:23]5[CH:28]=[CH:27][C:26]([O:29][C:30]([F:33])([F:32])[F:31])=[CH:25][CH:24]=5)[C:18]=4[N:19]=3)=[CH:9][C:8]=2[O:36][CH3:37])[CH:6]=1>C(=O)=O.CO>[Cl:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:12]=[CH:11][C:10]([NH:13][C:14]3[N:15]=[C:16]([NH:34][CH3:35])[C:17]4[CH2:22][CH2:21][C@H:20]([C:23]5[CH:24]=[CH:25][C:26]([O:29][C:30]([F:32])([F:33])[F:31])=[CH:27][CH:28]=5)[C:18]=4[N:19]=3)=[CH:9][C:8]=2[O:36][CH3:37])[CH:6]=1Participants
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
A racemic mixture of N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-7-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine (86 mg, 0.162 mmol from Example 97) was purified using chiral SFC to afford 36.6 mg of peak A (Example 97A) and 31.5 mg of peak B (Example 97B). SFC Method: Chiralpak OJ-H (4.6×250 mm, 5 μM), 30% methanol (0.1% diethylamine) in CO2, 35° C., flow rate 2.0 mL/min for 12 min, absorbance 268 nm, injection 5 μL of 2 mg/mL solution in methanol (multiple stacked injections), tR (peak A)=3.4 min, tR (peak B) 7.5 min. The absolute stereochemistry of individual enantiomers (Examples 97A and 97B) was not determined LC-MS and 1H NMR analytical data for the separated enantiomers was identical to the racemate (Example 97).
Workup
- customwas purified
- customto afford 36.6 mg of peak A (Example 97A) and 31.5 mg of peak B (Example 97B)
- custom=3.4 min, tR (peak B) 7.5 min
Sources & evidence
- ORD record
- ord-01da3d38a8a04a18a740f73d3984840c
- Source dataset
- uspto-grants-2014_01
- Patent number
- US08637525B2
Reaction notes
Loading…